Table I.
Patients’ features and bleeding sites.
| Overall N=205, n (%) |
DOAC N=50, n (%) |
VKA N=155, n (%) |
|
|---|---|---|---|
| Age, mean±SD range | 78±11 | 78±10 | 78±11 |
| 29–96 | 40–96 | 29–93 | |
|
| |||
| Male gender | 112 (55) | 33 (66) | 79 (51) |
|
| |||
| Indication for anticoagulation | |||
| Atrial fibrillation | 166 (81) | 47 (94) | 119 (77) |
| Venous thromboembolism | 11 (6) | 3 (6) | 10 (6) |
|
| |||
| Hypertension | 144 (70) | 32 (64) | 112 (72) |
|
| |||
| Renal failure | 55 (27) | 6 (12) | 49 (32) |
|
| |||
| Diabetes | 40 (19) | 11 (22) | 29 (19) |
|
| |||
| Previous bleeding | 62 (30) | 15 (30) | 47 (30) |
|
| |||
| Previous stroke | 33 (16) | 10 (20) | 23 (15) |
|
| |||
| Heart failure | 48 (23) | 15 (30) | 33 (21) |
|
| |||
| Vascular disease | 69 (34) | 13 (26) | 56 (36) |
|
| |||
| Malignancy | 32 (16) | 9 (18) | 23 (15) |
|
| |||
| NSAID/antiplatelet use | 17 (9) | 6 (12) | 13 (8) |
|
| |||
| Site | |||
| Gastrointestinal | 49 (24) | 20 (40) | 29 (19) |
| Genitourinary | 38 (18) | 17 (34) | 21 (13) |
| Respiratory tract | 50 (24) | 6 (12) | 44 (28) |
| Intramuscular | 23 (11) | 1 (2) | 22 (14) |
| Skin/subcutaneous | 36 (18) | 5 (10) | 31 (20) |
| Other | 9 (4) | 1 (2) | 8 (5) |
|
| |||
| Trauma | 50 (24) | 10 (20) | 40 (26) |
DOAC: direct oral anticoagulants; VKA: vitamin K antagonists; SD: standard deviation; NSAID: non-steroidal anti inflammatory drugs.